The University of Southampton
University of Southampton Institutional Repository

WS01.01 cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease

WS01.01 cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease
WS01.01 cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease
Objectives: cardiopulmonary exercise testing (CPET) provides prognostic information in cystic fibrosis (CF); however, its prognostic value for people with advanced CF lung disease (ACFLD) is currently unknown. We aimed to determine the prognostic value of CPET on the risk of death or lung transplant (LTX) within 2-years.

Methods: we retrospectively collected data from 20 CF-centers in Asia, Australia, Europe, and North America on adults with CF with a forced expiratory volume in 1 s (FEV1) ≤40% predicted who had performed a cycle ergometer CPET between January 2008 and December 2017. Time to death/LTX within 2-years after CPET was analysed using mixed Cox proportional hazards regression. Conditional inference trees were modelled to identify subgroups with an increased risk of death/LTX.

Results: in total, 174 patients (41.4% female) with mean±SD age of 30.0 ± 9.2 years and FEV1 30.9 ± 5.8% predicted were included. Forty-four patients (25.5%) died or underwent LTX within a mean ± SD follow-up period of 311 ± 191 days. Cox regression analysis adjusted forage, sex, and FEV1, revealed percent predicted peak oxygen uptake (VO2peak) and peak work rate (Wpeak) as significant predictors of death/LTX: adjusted hazard ratios per each additional ten more percent predicted were 0.60 (95% confidence interval [CI]: 0.43–0.90, P-value 0.008) and 0.60 (95% CI: 0.48–0.82, P-value <0.001), respectively. Tree-structured regression models, including a set of twelve prognostic factors for survival in CF, identified Wpeak to be most strongly associated with 2-year risk of death/LTX. Probability of death/LTX was 45.2% for those with a Wpeak ≤49.2% predicted versus 10.9% for those with a Wpeak >49.2% predicted (P <0.001).

Conclusion: CPET provides prognostic information in ACFLD and Wpeak appears to be a promising marker for aiding clinical decision-making with regard to referral for and timing of LTX.
1569-1993
S1
Radtke, T.
f79ede09-9f79-4322-828a-58604c31db14
Urquhart, D.S.
601a5225-68dc-41c2-aa42-c7212d68bebb
Braun, J.
024c00be-9a67-453c-9e95-742b0b2da834
Barry, P.
933121b4-5e1c-44af-9474-80132236b5cc
Waller, I.
90feafe1-b4ab-47f2-b3ee-72e77eade56d
Petch, N.
d9508f0d-6064-4b47-8a39-f38a74ce69c8
Mei-Zahav, M.
a33dfcca-3222-4e3f-8773-e6fab3a9abbf
Kramer, M. R.
1b8e1173-cc0b-4486-b76c-3ca12c8f8fa3
Hua-Huy, T.
72c665f7-1acd-46de-b7f9-af5cc69f2d8b
Dinh-Xuan, A.T.
99d953bf-2138-493c-a7a1-648ae849f7a0
Innes, J.A.
b7e49aa9-771f-47ce-8c5d-88e5bb9786a8
Mcarthur, S.
bb95ef7e-3f07-4dee-b871-755f1d5b4fae
Sovtic, A.
166455f3-620b-4742-b3c0-0f1fd8fc593e
Gojsina, B.
3b2732a3-0bf3-4382-a8d9-2d2e84f23d11
Verges, S.
870d656b-6ae0-4b76-877d-9403de63a4aa
De Maat, T.
23e7b270-8d49-4ac5-8235-f63474676e72
Morrison, L.
fba2ab45-292e-4a5d-bf7e-acde5c1b93c8
Wood, J.
ca695b34-b631-43cc-9709-90ae3d302b7a
Crute, S.
26444b1a-5de3-4177-a943-e3ff40af53e6
Williams, C.A.
be592f8d-fac8-4f37-9ca1-52f445b62fb4
Tomlinson, O.W.
e5ac12ad-6d1c-450c-80c2-d2a4cdb789cc
Bar-Yoseph, R.
2660d392-9e5a-4294-8fda-6bd4508a8a91
Hebestreit, A.
461facaf-4740-45e0-82f9-576d815213d5
Quon, B.S.
1a35e83a-8a82-4b7d-b0c3-d712ff8c2a9f
Kwong, E.
dd06ca9a-65a9-4344-bc20-a012ae22fa45
Saynor, Z.L.
a4357c7d-db59-4fa5-b24f-58d2f7e74e39
Causer, A.J.
17d4182a-d52f-4b92-89fc-99cec813e98d
Stephenson, A.I.
b6310491-64c1-402a-bb40-f0f848b015e3
Schneiderman, J.E.
505930d0-b7c3-4c6f-9098-3939987d1475
Shaw, M.
1b36f459-3b68-4275-990f-d958ef9142f4
Dwyer, T.
ff72c224-fc2f-491e-a88a-8559fb3fe953
Stevens, D.
484c675c-e346-46e2-a432-47e80e17958b
Remus, N.
04b03001-3daf-4a4f-832b-1f2a5974d964
Douvry, B.
29dc366b-175f-4032-b425-3d7c3235e995
Foster, K.
439451d5-1d44-4f76-a6c1-26ccda8ffaf7
Ratjen, F.
6fa9fdb7-49f8-4d42-b584-d95637ddf8ce
Benden, C.
92bc43c1-5756-4778-a988-4cfd1d2df53c
Hebestreit, H.
c6b67a0b-20d3-480a-ac57-92d2de878b82
et al.
Radtke, T.
f79ede09-9f79-4322-828a-58604c31db14
Urquhart, D.S.
601a5225-68dc-41c2-aa42-c7212d68bebb
Braun, J.
024c00be-9a67-453c-9e95-742b0b2da834
Barry, P.
933121b4-5e1c-44af-9474-80132236b5cc
Waller, I.
90feafe1-b4ab-47f2-b3ee-72e77eade56d
Petch, N.
d9508f0d-6064-4b47-8a39-f38a74ce69c8
Mei-Zahav, M.
a33dfcca-3222-4e3f-8773-e6fab3a9abbf
Kramer, M. R.
1b8e1173-cc0b-4486-b76c-3ca12c8f8fa3
Hua-Huy, T.
72c665f7-1acd-46de-b7f9-af5cc69f2d8b
Dinh-Xuan, A.T.
99d953bf-2138-493c-a7a1-648ae849f7a0
Innes, J.A.
b7e49aa9-771f-47ce-8c5d-88e5bb9786a8
Mcarthur, S.
bb95ef7e-3f07-4dee-b871-755f1d5b4fae
Sovtic, A.
166455f3-620b-4742-b3c0-0f1fd8fc593e
Gojsina, B.
3b2732a3-0bf3-4382-a8d9-2d2e84f23d11
Verges, S.
870d656b-6ae0-4b76-877d-9403de63a4aa
De Maat, T.
23e7b270-8d49-4ac5-8235-f63474676e72
Morrison, L.
fba2ab45-292e-4a5d-bf7e-acde5c1b93c8
Wood, J.
ca695b34-b631-43cc-9709-90ae3d302b7a
Crute, S.
26444b1a-5de3-4177-a943-e3ff40af53e6
Williams, C.A.
be592f8d-fac8-4f37-9ca1-52f445b62fb4
Tomlinson, O.W.
e5ac12ad-6d1c-450c-80c2-d2a4cdb789cc
Bar-Yoseph, R.
2660d392-9e5a-4294-8fda-6bd4508a8a91
Hebestreit, A.
461facaf-4740-45e0-82f9-576d815213d5
Quon, B.S.
1a35e83a-8a82-4b7d-b0c3-d712ff8c2a9f
Kwong, E.
dd06ca9a-65a9-4344-bc20-a012ae22fa45
Saynor, Z.L.
a4357c7d-db59-4fa5-b24f-58d2f7e74e39
Causer, A.J.
17d4182a-d52f-4b92-89fc-99cec813e98d
Stephenson, A.I.
b6310491-64c1-402a-bb40-f0f848b015e3
Schneiderman, J.E.
505930d0-b7c3-4c6f-9098-3939987d1475
Shaw, M.
1b36f459-3b68-4275-990f-d958ef9142f4
Dwyer, T.
ff72c224-fc2f-491e-a88a-8559fb3fe953
Stevens, D.
484c675c-e346-46e2-a432-47e80e17958b
Remus, N.
04b03001-3daf-4a4f-832b-1f2a5974d964
Douvry, B.
29dc366b-175f-4032-b425-3d7c3235e995
Foster, K.
439451d5-1d44-4f76-a6c1-26ccda8ffaf7
Ratjen, F.
6fa9fdb7-49f8-4d42-b584-d95637ddf8ce
Benden, C.
92bc43c1-5756-4778-a988-4cfd1d2df53c
Hebestreit, H.
c6b67a0b-20d3-480a-ac57-92d2de878b82

Radtke, T., Urquhart, D.S. and Braun, J. , et al. (2023) WS01.01 cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis, 22 (Suppl. 2), S1. (doi:10.1016/S1569-1993(23)00187-X).

Record type: Article

Abstract

Objectives: cardiopulmonary exercise testing (CPET) provides prognostic information in cystic fibrosis (CF); however, its prognostic value for people with advanced CF lung disease (ACFLD) is currently unknown. We aimed to determine the prognostic value of CPET on the risk of death or lung transplant (LTX) within 2-years.

Methods: we retrospectively collected data from 20 CF-centers in Asia, Australia, Europe, and North America on adults with CF with a forced expiratory volume in 1 s (FEV1) ≤40% predicted who had performed a cycle ergometer CPET between January 2008 and December 2017. Time to death/LTX within 2-years after CPET was analysed using mixed Cox proportional hazards regression. Conditional inference trees were modelled to identify subgroups with an increased risk of death/LTX.

Results: in total, 174 patients (41.4% female) with mean±SD age of 30.0 ± 9.2 years and FEV1 30.9 ± 5.8% predicted were included. Forty-four patients (25.5%) died or underwent LTX within a mean ± SD follow-up period of 311 ± 191 days. Cox regression analysis adjusted forage, sex, and FEV1, revealed percent predicted peak oxygen uptake (VO2peak) and peak work rate (Wpeak) as significant predictors of death/LTX: adjusted hazard ratios per each additional ten more percent predicted were 0.60 (95% confidence interval [CI]: 0.43–0.90, P-value 0.008) and 0.60 (95% CI: 0.48–0.82, P-value <0.001), respectively. Tree-structured regression models, including a set of twelve prognostic factors for survival in CF, identified Wpeak to be most strongly associated with 2-year risk of death/LTX. Probability of death/LTX was 45.2% for those with a Wpeak ≤49.2% predicted versus 10.9% for those with a Wpeak >49.2% predicted (P <0.001).

Conclusion: CPET provides prognostic information in ACFLD and Wpeak appears to be a promising marker for aiding clinical decision-making with regard to referral for and timing of LTX.

This record has no associated files available for download.

More information

e-pub ahead of print date: 9 June 2022
Published date: 9 June 2023
Additional Information: 46th European Cystic Fibrosis Conference ; Conference date: 07-06-2002 Through 10-06-2023
Venue - Dates: 46th European Cystic Fibrosis Conference, , Vienna, Austria, 2023-06-07 - 2023-06-10

Identifiers

Local EPrints ID: 493871
URI: http://eprints.soton.ac.uk/id/eprint/493871
ISSN: 1569-1993
PURE UUID: 35696eb0-fd59-434d-a3b8-806d03d9434c
ORCID for Z.L. Saynor: ORCID iD orcid.org/0000-0003-0674-8477

Catalogue record

Date deposited: 16 Sep 2024 16:44
Last modified: 17 Sep 2024 02:09

Export record

Altmetrics

Contributors

Author: T. Radtke
Author: D.S. Urquhart
Author: J. Braun
Author: P. Barry
Author: I. Waller
Author: N. Petch
Author: M. Mei-Zahav
Author: M. R. Kramer
Author: T. Hua-Huy
Author: A.T. Dinh-Xuan
Author: J.A. Innes
Author: S. Mcarthur
Author: A. Sovtic
Author: B. Gojsina
Author: S. Verges
Author: T. De Maat
Author: L. Morrison
Author: J. Wood
Author: S. Crute
Author: C.A. Williams
Author: O.W. Tomlinson
Author: R. Bar-Yoseph
Author: A. Hebestreit
Author: B.S. Quon
Author: E. Kwong
Author: Z.L. Saynor ORCID iD
Author: A.J. Causer
Author: A.I. Stephenson
Author: J.E. Schneiderman
Author: M. Shaw
Author: T. Dwyer
Author: D. Stevens
Author: N. Remus
Author: B. Douvry
Author: K. Foster
Author: F. Ratjen
Author: C. Benden
Author: H. Hebestreit
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×